Search results for: 'platform deal'

Stem Cell Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Cancer Diagnostic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Gene Therapy Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Essential Benchmark Data for Dealmakers  | Global coverage | Updated to 2024 | Over a decade of royalty rates | Deal financials | Contract documents | Royalty rate trends

Cancer Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Central Nervous System (CNS) Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2019 to 2024

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

Global Specialty Pharmaceutical Partnering Terms and Agreements 2019 to 2024 report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 provides comprehensive understanding and unprecedented access to clinical stage partnering agreements entered into by the world's leading biopharma companies

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.